

## ENLUXTRA DIFFERENCE

Every now and then we are confronted with a question: Enluxtra looks almost like any other pad dressing, what makes it unique, what is its advantage?

True, Enluxtra dressing's appearance may be similar to pad dressings you are used to, but the fact is – it is made of proprietary superabsorbent material VERY different from anything you see on the market.

FIRST of all, Enluxtra is the only cuttable superabsorbent dressing on the market today, with the highest available absorbing capability. Unlike its competitors, Enluxtra is not just a sachet filled with superabsorbent powder, but rather a structurally sound pad that feels like thick soft fiber fabric, completely customizable to your application needs.

SECOND – Enluxtra's absorption process differs from that of its competitors.

Exudate consists of many components: water, high molecular weight components, bacteria, pieces of liquefied necrotic debris and slough. It's how each dressing handles these components that makes a huge difference.

For example, when other absorbing/gelling fiber dressings (alginate- or CMC-based) are applied to the wound, they absorb water and form a continuous layer of gel over the wound surface. However, wound exudate is much more than just water, so when the dressing is on, while the water is absorbed, all other exudate components that ideally MUST be properly and timely evacuated from the wound bed, are left behind on the wound surface under the dressing. This condensed soup of bacteria, slough, necrotic tissue, toxins, salts, and other high molecular weight components is then distributed over the dry parts of the wound, wound edges, and healthy skin around the wound causing wound deterioration and re-infection. Some foams can absorb more of the heavier components than common gelling fibers, but they also usually easily release everything that was absorbed back to the wound and skin around, causing maceration and wound re-infection.

Additionally, the newly formed continuous gel layer blocks oxygen as the diffusion rate of gases in continuous gels is approximately 10,000 times lower than in the air. This creates anaerobic environment over the wound surface, which supports accelerated growth of many dangerous pathogens, increasing bioburden and further worsening the wound condition.

Enluxtra's absorption process takes a completely different route.

First, ALL exudate components are drawn in and sequestered inside the dressing material. Enluxtra dressing's porous wound contact surface easily allows for even the heavier exudate components to enter the dressing material. Then water is chemically bound to polymer molecules and becomes unavailable to the sequestered microorganisms. Without water supply they cannot replicate, and soon die inside the dressing as the life cycle of individual bacteria is very short. Additionally, because water is chemically bound, it becomes impossible to squeeze anything out of the dressing to the wound.

Each freshly applied dressing decreases bioburden, repairs the periwound area, and prevents introduction of irritants and pathogens that perpetuate bacterial growth. THIS is why pressure wounds are not deteriorating under Enluxtra.

THIRD – Enluxtra is the only superabsorbent dressing on the market that has a hydrating capability. It is, in fact, a unique quality for a superabsorbent dressing. Other superabsorbents will quickly desiccate the wound bed and wound edges, causing cell lysis and micro-necrosis, and resulting in inflammation and infection. Enluxtra, however, uses embedded hydrogel to prevent damage to dry areas. Therefore, you can safely use Enluxtra even on dry wounds and not worry about desiccating them.

THE MOST DIFFERENTIATING FEATURE of Enluxtra is its localized action. Enluxtra is able to absorb AND hydrate when and where needed. Most wounds have both exuding and dry areas, and Enluxtra easily adapts its function to each of these areas, all at the same time. The exudate is absorbed at the exuding part of the wound, but dry parts stay hydrated, and there is never any exudate transfer along the wound.

For clinical studies please review our clinical evidence page:  
<http://www.enluxtrawoundcare.com/clinical-evidence.html> .

There are numerous Enluxtra studies published in professional literature and presented at the conferences, even though Enluxtra is relatively new, having been on the market for only 3 years. Also, there are several documented case study series with detailed descriptions and photos. We are constantly working on collecting new studies, many of which will be published next year.

BUT — and this is very important!! – to see the difference in treatment outcomes you must follow a few simple rules when using Enluxtra: always fully cover the periwound area (THE most important rule), keep the dressing in contact with the wound bed at all times, change it more often on sloughy/necrotic wounds, until the wound is free of slough (normally in 1-2 weeks). If the rules are not followed, the effect of Enluxtra treatment will be diminished.

We would suggest that you take a second look to see how Enluxtra could help you in your most difficult cases. It is designed to make your life easier.

Attend our live clinical webinar, it is not marketing-based but purposed for education only and you can ask lots of questions there.